U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2O2.ClH
Molecular Weight 230.691
Optical Activity ( + )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Solriamfetol Hydrochloride

SMILES

Cl.N[C@@H](COC(N)=O)CC1=CC=CC=C1

InChI

InChIKey=KAOVAAHCFNYXNJ-SBSPUUFOSA-N
InChI=1S/C10H14N2O2.ClH/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8;/h1-5,9H,6-7,11H2,(H2,12,13);1H/t9-;/m1./s1

HIDE SMILES / InChI
ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wakefulness in adult patients with hypersomnia associated with narcolepsy or obstructive sleep apnoea.The US FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.9 µM [IC50]
4.4 µM [IC50]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
499 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLRIAMFETOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5273 ng × h/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLRIAMFETOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 h
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLRIAMFETOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Other AEs: Decreased appetite, Insomnia...
Other AEs:
Decreased appetite (9%)
Insomnia (5%)
Anxiety (6%)
Headache (16%)
Palpitations (2%)
Nausea (7%)
Dry mouth (4%)
Constipation (3%)
Agitation (<2%)
Bruxism (<2%)
Irritability (<2%)
Cough (<2%)
Hyperhidrosis (<2%)
Feeling jittery (<2%)
Thirst (<2%)
Chest discomfort (<2%)
Chest pain (<2%)
Weight decreased (<2%)
Sources:
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Disc. AE: Anxiety, Palpitations...
Other AEs: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Anxiety (0.5%)
Palpitations (0.5%)
Restlessness (0.5%)
Other AEs:
Headache (13%)
Nausea (9%)
Decreased appetite (8%)
Anxiety (7%)
Dry mouth (4%)
Diarrhea (5%)
Sources:
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (7%)
Nausea (7%)
Decreased appetite (2%)
Anxiety (2%)
Dry mouth (2%)
Diarrhea (2%)
Sources:
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (9%)
Nausea (5%)
Decreased appetite (7%)
Anxiety (3%)
Dry mouth (3%)
Diarrhea (4%)
Sources:
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Other AEs: Decreased appetite, Anxiety...
Other AEs:
Decreased appetite (6%)
Anxiety (4%)
Irritability (3%)
Dizziness (2%)
Palpitations (3%)
Nausea (8%)
Diarrhea (4%)
Abdominal pain (3%)
Dry mouth (3%)
Feeling jittery (3%)
Chest discomfort (2%)
Hyperhidrosis (2%)
Bruxism (<2%)
Restlessness (<2%)
Disturbance in attention (<2%)
Tremor (<2%)
Cough (<2%)
Dyspnea (<2%)
Constipation (<2%)
Vomiting (<2%)
Weight decreased (<2%)
Sources:
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
Other AEs: Blood pressure systolic increased, Blood pressure diastolic increased...
Other AEs:
Blood pressure systolic increased
Blood pressure diastolic increased
Heart rate increased
Sources:
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Other AEs: Insomnia, Headache...
Other AEs:
Insomnia (grade 1, 21.9%)
Headache (grade 1, 15.6%)
Hypervigilance (grade 1, 9.4%)
Decreased appetite (grade 1, 9.4%)
Nausea (grade 1, 9.4%)
Insomnia (grade 1, 21.9%)
Headache (grade 1, 12.5%)
Hypervigilance (grade 1, 12.5%)
Decreased appetite (grade 1, 9.4%)
Nausea (grade 1, 6.3%)
Sources:
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Disc. AE: Blood pressure increased, Nervousness...
Other AEs: Hypervigilance, Elevated mood...
AEs leading to
discontinuation/dose reduction:
Blood pressure increased (grade 1, 2.4%)
Nervousness (grade 1, 2.4%)
Other AEs:
Hypervigilance (42.9%)
Elevated mood (23.8%)
Dry mouth (21.4%)
Nausea (21.4%)
Feeling of relaxation (19%)
Decreased appetite (19%)
Hyperhidrosis (19%)
Insomnia (16.7%)
Headache (14.3%)
Restlessness (14.3%)
Palpitations (11.9%)
Paresthesia (7.1%)
Sources:
150 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 417
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Sex: M+F
Population Size: 417
Sources:
Disc. AE: Blood pressure increased, Hypertension...
AEs leading to
discontinuation/dose reduction:
Blood pressure increased (0.48%)
Hypertension (0.24%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 16%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Palpitations 2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Constipation 3%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Dry mouth 4%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Insomnia 5%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Anxiety 6%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Nausea 7%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Decreased appetite 9%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Agitation <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Bruxism <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Chest discomfort <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Chest pain <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Cough <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Feeling jittery <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Hyperhidrosis <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Irritability <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Thirst <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Weight decreased <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
Anxiety 0.5%
Disc. AE
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Palpitations 0.5%
Disc. AE
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Restlessness 0.5%
Disc. AE
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Headache 13%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Dry mouth 4%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Diarrhea 5%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Anxiety 7%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Decreased appetite 8%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Nausea 9%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
Anxiety 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Decreased appetite 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Diarrhea 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Dry mouth 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Headache 7%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Nausea 7%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
Anxiety 3%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Dry mouth 3%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Diarrhea 4%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Nausea 5%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Decreased appetite 7%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Headache 9%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
Chest discomfort 2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Dizziness 2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Hyperhidrosis 2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Abdominal pain 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Dry mouth 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Feeling jittery 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Irritability 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Palpitations 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Anxiety 4%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Diarrhea 4%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Decreased appetite 6%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Nausea 8%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Bruxism <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Constipation <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Cough <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Disturbance in attention <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Dyspnea <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Restlessness <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Tremor <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Vomiting <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Weight decreased <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
Blood pressure diastolic increased
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
Blood pressure systolic increased
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
Heart rate increased
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
Headache grade 1, 12.5%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Hypervigilance grade 1, 12.5%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Headache grade 1, 15.6%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Insomnia grade 1, 21.9%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Insomnia grade 1, 21.9%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Nausea grade 1, 6.3%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Decreased appetite grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Decreased appetite grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Hypervigilance grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Nausea grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
Palpitations 11.9%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Headache 14.3%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Restlessness 14.3%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Insomnia 16.7%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Decreased appetite 19%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Feeling of relaxation 19%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Hyperhidrosis 19%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Dry mouth 21.4%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Nausea 21.4%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Elevated mood 23.8%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Hypervigilance 42.9%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Paresthesia 7.1%
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Blood pressure increased grade 1, 2.4%
Disc. AE
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Nervousness grade 1, 2.4%
Disc. AE
1200 mg 1 times / day single, oral
Highest studied dose
healthy, mean age 29.3 years
n = 42
Hypertension 0.24%
Disc. AE
150 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 417
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Sex: M+F
Population Size: 417
Sources:
Blood pressure increased 0.48%
Disc. AE
150 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 417
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Sex: M+F
Population Size: 417
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [IC50 146 uM]
weak [IC50 211 uM]
weak [IC50 360 uM]
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
2015 Sep
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
2016 Jul 1
New developments in the management of narcolepsy.
2017

Sample Use Guides

The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.
Route of Administration: Oral
Solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity (Ki=14.2 uM and 3.7 uM, respectively), and inhibits the reuptake of dopamine and norepinephrine with low potency (IC50 =2.9 uM and 4.4 uM, respectively). Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 uM) and does not inhibit serotonin reuptake (IC50 > 100 uM).
Name Type Language
Solriamfetol Hydrochloride
USAN  
Official Name English
Solriamfetol hydrochloride [WHO-DD]
Common Name English
ADX-N05 HYDROCHLORIDE
Code English
ADX-N-05 HYDROCHLORIDE
Code English
YKP-10A HYDROCHLORIDE
Code English
SOLRIAMFETOL HYDROCHLORIDE [ORANGE BOOK]
Common Name English
(2R)-2-Amino-3-phenylpropyl carbamate, monohydrochloride
Systematic Name English
BENZENEPROPANOL, .BETA.-AMINO-, 1-CARBAMATE, HYDROCHLORIDE (1:1), (.BETA.R)-
Systematic Name English
SKL-N-05 HYDROCHLORIDE
Code English
R-228060 HYDROCHLORIDE
Code English
SOLRIAMFETOL HYDROCHLORIDE [USAN]
Common Name English
JZP-110 HYDROCHLORIDE
Code English
SOLRIAMFETOL HYDROCHLORIDE [MI]
Common Name English
(R)-(+)-2-AMINO-1-CARBAMOYLOXY-3-PHENYLPROPANE HYDROCHLORIDE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 375112
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
Code System Code Type Description
RXCUI
2121750
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
NCI_THESAURUS
C170379
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID101027927
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
MERCK INDEX
m12132
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
MESH
C470510
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
FDA UNII
K7RO88SP7A
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
USAN
EF-114
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
DRUG BANK
DBSALT002865
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
PUBCHEM
67583702
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
CAS
178429-65-7
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY
SMS_ID
100000180154
Created by admin on Fri Dec 15 15:28:54 GMT 2023 , Edited by admin on Fri Dec 15 15:28:54 GMT 2023
PRIMARY